Endometrial cancer, one of the most common gynecological malignancies worldwide, has been quietly rising in incidence for decades, and for patients whose disease advances or recurs, the therapeutic landscape remains frustratingly thin. Now, a team of researchers at The First Affiliated Hospital of Zhengzhou University in China has identified a molecular driver of this aggressiveness that has been hiding in plain sight: Keratin 17, a structural protein better known for its role in skin and hair follicles. According to a new study published in the Journal of Cancer Research and Clinical Oncology, KRT17 is markedly overexpressed in endometrial tumors, tracks closely with poor patient survival, and—most strikingly—appears to actively fuel the cancer’s invasive behavior by triggering epithelial-mesenchymal transition, the cellular program that allows tumor cells to break free and spread.
The finding is significant because keratins have long been treated mainly as identity markers rather than functional players. Intermediate filament proteins such as keratins form part of the cytoskeletal scaffold that gives epithelial cells their shape and resilience. Yet over the past two decades, evidence has accumulated that certain keratins, particularly those normally absent from a given tissue but induced under stress—so-called stress keratins—do far more than provide mechanical support. KRT17, a type I intermediate filament, has been implicated in tumor progression in several other cancers, promoting proliferation, survival under metabolic stress, and motility. Whether it played a comparable role in endometrial cancer, however, had remained an open question.
To answer it, the research team led by Xiaole Song, Xuerou Chen, and corresponding author Fang Ren combined large-scale bioinformatics with laboratory experiments at single-cell resolution. Mining data from The Cancer Genome Atlas for uterine corpus endometrial carcinoma, the researchers found that KRT17 expression was significantly elevated in endometrial cancer tissues compared with healthy endometrium. Crucially, the elevation was not merely a molecular curiosity. Patients whose tumors expressed high levels of KRT17 showed reduced overall survival and adverse clinical outcomes, establishing the protein as a marker of aggressive disease and a potential prognostic indicator that could eventually complement existing clinical classification.
But tissue-level averages can be deceiving. A bulk tumor sample contains a mixture of malignant epithelial cells, immune cells, fibroblasts, endothelial cells, and other stromal components, and gene signatures measured across such a mixture may reflect shifts in cellular composition rather than changes within the cancer cells themselves. To disentangle this, the team turned to single-cell RNA sequencing, a technique that captures the transcriptomes of individual cells and allows researchers to pinpoint exactly which cell types are expressing a given gene. The scRNA-seq analysis revealed that KRT17 was concentrated in the malignant epithelial cells of endometrial tumors, not in the surrounding microenvironment, confirming that the signal emanated from the cancer cells proper.
With the cellular source identified, the researchers then asked what KRT17-expressing tumor cells were actually doing. Differential expression analysis compared the gene expression profiles of KRT17-high and KRT17-low malignant cells, and pathway enrichment analyses were applied to the results to identify the biological programs associated with high KRT17. The answer pointed unambiguously to one process: epithelial-mesenchymal transition, or EMT. In EMT, epithelial cells—which are normally tightly packed, polarized, and anchored to their neighbors—shed their identity and acquire mesenchymal characteristics, becoming motile, invasive, and resistant to cell death. This transition is a well-established mechanism by which carcinomas invade surrounding tissue, enter blood and lymphatic vessels, and seed metastases at distant sites. The significant enrichment of KRT17 in the EMT pathway suggested that the keratin was not a passive bystander in this process but an active participant.
To test that hypothesis directly, the team performed loss-of-function experiments in endometrial cancer cells in the laboratory. Using stable knockdown to suppress KRT17 expression, they measured the effects on the core malignant behaviors of the cells. The results were consistent across multiple assays: cells lacking KRT17 proliferated more slowly, migrated less efficiently across wound and transwell-style assays, and showed a markedly reduced capacity to invade through extracellular-matrix-like barriers. The researchers also assessed spheroid formation—the ability of cells to grow into three-dimensional clusters that mimic tumor architecture—and found this too was significantly impaired without KRT17. In parallel, the knockdown altered the expression of key EMT markers, the molecular signposts that distinguish epithelial from mesenchymal states, indicating that removing KRT17 pushed the cells back toward a less invasive, more epithelial phenotype.
The in vitro findings set the stage for the decisive test: does KRT17 matter in a living organism? Using animal models of endometrial cancer, the researchers showed that tumors engineered with KRT17 knockdown grew substantially less than control tumors. Moreover, analysis of the tumor tissue demonstrated that suppressing KRT17 reversed the EMT process in vivo, shifting the balance of EMT marker expression back toward the epithelial state. Taken together with the cell culture data, the results establish KRT17 as a functional driver of endometrial cancer progression rather than a mere correlate—its presence enables the proliferation, migration, and invasion that make this disease deadly in its advanced stages.
The mechanistic picture that emerges is one in which KRT17 sits at the intersection of structural biology and signaling. The study’s pathway analyses connect KRT17 expression to a broader network of cancer-related pathways, including signaling cascades such as AKT/mTOR, which regulates cell growth and metabolism, and HIF-1α signaling, which governs the cellular response to low oxygen—a hallmark of the tumor microenvironment. Other genes tied to aggressive behavior, including MCL1, which promotes cell survival, and VEGF, which drives blood vessel formation, feature in the landscape of KRT17-associated biology. The single-cell and bulk tumor data also situate KRT17 within the molecular classification of endometrial cancer, which includes microsatellite instability-high, mismatch repair-deficient, and no specific molecular profile categories—context that will matter for determining which patient groups stand to benefit most from KRT17-directed approaches.
The clinical implications are twofold. First, as a biomarker, KRT17 could help stratify patients at diagnosis, flagging tumors likely to behave aggressively and guiding the intensity of surveillance and adjuvant treatment. The correlation between high KRT17 and reduced overall and disease-specific survival suggests it could be measured by established pathology techniques such as immunohistochemistry, which is already routine in clinical laboratories. Second, and more ambitiously, KRT17 represents a potential therapeutic target. The knockdown experiments demonstrate that reducing KRT17 levels cripples the malignant phenotype across the board—in proliferation, migration, invasion, and tumor-forming capacity. Translating that into a drug is no trivial matter, since targeting a cytoskeletal protein expressed in some normal tissues carries risks, but the study provides the proof of principle that interfering with KRT17 biology can blunt tumor progression and reverse EMT.
The researchers also emphasize the methodological significance of their approach. By integrating single-cell transcriptomics with bulk-level bioinformatics and classical wet-lab validation, the study exemplifies the modern pipeline for target discovery: computational screens generate hypotheses at population scale, single-cell data assign those hypotheses to specific cell types, and functional assays verify causation. This tiered strategy is increasingly seen as essential in cancer research, where bulk analyses alone frequently misattribute signals to the wrong cells. The fact that the KRT17-EMT link held up at every level—from patient survival data through single-cell expression profiles to animal models—lends the finding unusual robustness.
Much work remains before these results reach the clinic. The precise molecular mechanisms by which KRT17 activates or maintains EMT in endometrial cancer cells—whether through direct interactions with signaling proteins, effects on cell mechanics and adhesion, or regulation of transcriptional programs—will need to be worked out in detail. Prospective studies will be required to validate KRT17 as an independent prognostic marker across the diverse molecular subtypes of the disease, and any therapeutic development will need to address the question of specificity. Nevertheless, the study adds a compelling new name to the roster of molecules implicated in endometrial cancer progression, and it does so at a time when new targets for advanced and recurrent disease are urgently needed. For a cancer whose incidence continues to climb and whose treatment options narrow sharply once it spreads, every well-validated vulnerability matters—and Keratin 17, the humble structural filament turned aggressive driver, may prove to be one of the most actionable yet.
Subject of Research: The role of Keratin 17 (KRT17) in driving endometrial cancer progression through epithelial-mesenchymal transition, using single-cell transcriptomics, bioinformatics, and in vitro and in vivo functional studies
Subject of Research: Cancer
Article Title: Keratin 17 drives endometrial cancer aggressiveness via epithelial-mesenchymal transition: a single-cell transcriptomic and integrative bioinformatics study
Article References: Song, X., Chen, X., Liu, Q., Ma, Y., Zhang, X., & Ren, F. (2026). Keratin 17 drives endometrial cancer aggressiveness via epithelial-mesenchymal transition: a single-cell transcriptomic and integrative bioinformatics study. Journal of Cancer Research and Clinical Oncology. https://doi.org/10.1007/s00432-026-06561-2
Image Credits: AI Generated
DOI: 10.1007/s00432-026-06561-2
Keywords: Endometrial cancer, Keratin 17, KRT17, Epithelial-mesenchymal transition, Single-cell RNA sequencing, Migration, Proliferation, Tumor progression, Prognosis, EMT markers, Tumor microenvironment
Cite Scienmag News
APA MLA Chicago
Nathaniel Bowman. (September 10, 2026). Keratin 17 promotes endometrial cancer aggressiveness through epithelial-mesenchymal transition. Scienmag. https://scienmag.com/keratin-17-promotes-endometrial-cancer-aggressiveness-through-epithelial-mesenchymal-transition/
Nathaniel Bowman. “Keratin 17 promotes endometrial cancer aggressiveness through epithelial-mesenchymal transition.” Scienmag, 10 September 2026, https://scienmag.com/keratin-17-promotes-endometrial-cancer-aggressiveness-through-epithelial-mesenchymal-transition/. Accessed 10 September 2026.
Nathaniel Bowman. “Keratin 17 promotes endometrial cancer aggressiveness through epithelial-mesenchymal transition.” Scienmag. September 10, 2026. https://scienmag.com/keratin-17-promotes-endometrial-cancer-aggressiveness-through-epithelial-mesenchymal-transition/
Copy citation Download RIS
Tags: cellular mechanisms of endometrial cancer spreadcellular programs promoting tumor spreadcytoskeletal proteins in cancer metastasiscytoskeletal proteins in tumor aggressivenessendometrial cancer progressionepithelial-mesenchymal transition in endometrial tumorsepithelial-mesenchymal transition in tumorskeratin 17 in cancerkeratin 17 role in cancer aggressivenesskeratin proteins in cancer biologykeratin proteins in cancer metastasisKRT17 overexpression and patient prognosisKRT17 overexpression in gynecological cancersmolecular drivers of endometrial cancermolecular drivers of endometrial cancer recurrencemolecular mechanisms of endometrial cancer invasionprognostic markers in endometrial carcinomarole of intermediate filament proteins in cancerrole of stress keratins in cancerstress keratins in tumor developmenttherapeutic targets in endometrialtherapeutic targets in endometrial cancertumor invasiveness and keratin 17
